RGEN Repligen Corp

Price (delayed)

$307.37

Market cap

$16.9B

P/E Ratio

166.15

Dividend/share

N/A

EPS

$1.85

Enterprise value

$16.47B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights
RGEN's gross profit has soared by 74% YoY and by 20% QoQ
The revenue has soared by 68% YoY and by 17% from the previous quarter
RGEN's quick ratio has dropped by 82% year-on-year
The stock's P/E is 31% above its 5-year quarterly average of 126.9 and 14% above its last 4 quarters average of 146.1

Key stats

What are the main financial stats of RGEN
Market
Shares outstanding
54.98M
Market cap
$16.9B
Enterprise value
$16.47B
Valuations
Price to earnings (P/E)
166.15
Price to book (P/B)
10.53
Price to sales (P/S)
33.2
EV/EBIT
134.57
EV/EBITDA
106.94
EV/Sales
32.39
Earnings
Revenue
$508.51M
EBIT
$122.39M
EBITDA
$154.01M
Free cash flow
$40.18M
Per share
EPS
$1.85
Free cash flow per share
$0.73
Book value per share
$29.2
Revenue per share
$9.26
TBVPS
$20.42
Balance sheet
Total assets
$2.02B
Total liabilities
$412.9M
Debt
$305.99M
Equity
$1.6B
Working capital
$651.49M
Liquidity
Debt to equity
0.19
Current ratio
2.96
Quick ratio
2.52
Net debt/EBITDA
-2.78
Margins
EBITDA margin
30.3%
Gross margin
58.8%
Net margin
19.7%
Operating margin
24.2%
Efficiency
Return on assets
5.5%
Return on equity
6.9%
Return on invested capital
36.9%
Return on capital employed
7.3%
Return on sales
24.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGEN stock price

How has the Repligen stock price performed over time
Intraday
-4.92%
1 week
0.43%
1 month
11.43%
1 year
113.01%
YTD
60.4%
QTD
53.98%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$508.51M
Gross profit
$298.98M
Operating income
$123M
Net income
$99.93M
Gross margin
58.8%
Net margin
19.7%
The operating income has soared by 172% YoY and by 30% from the previous quarter
The net margin has soared by 93% YoY and by 7% from the previous quarter
RGEN's gross profit has soared by 74% YoY and by 20% QoQ
The revenue has soared by 68% YoY and by 17% from the previous quarter

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
P/E
166.15
P/B
10.53
P/S
33.2
EV/EBIT
134.57
EV/EBITDA
106.94
EV/Sales
32.39
The stock's P/E is 31% above its 5-year quarterly average of 126.9 and 14% above its last 4 quarters average of 146.1
RGEN's EPS is up by 24% since the previous quarter
The P/B is 111% more than the 5-year quarterly average of 5.0 and 55% more than the last 4 quarters average of 6.8
Repligen's equity has increased by 46% YoY and by 3% QoQ
RGEN's P/S is 113% above its 5-year quarterly average of 15.6 and 37% above its last 4 quarters average of 24.3
The revenue has soared by 68% YoY and by 17% from the previous quarter

Efficiency

How efficient is Repligen business performance
RGEN's ROA has soared by 150% year-on-year and by 17% since the previous quarter
The return on equity has surged by 138% year-on-year and by 15% since the previous quarter
RGEN's return on sales has surged by 64% year-on-year and by 11% since the previous quarter
The ROIC has grown by 37% from the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
RGEN's quick ratio has dropped by 82% year-on-year
Repligen's current ratio has shrunk by 81% YoY
The debt is 81% less than the equity
Repligen's equity has increased by 46% YoY and by 3% QoQ
Repligen's debt to equity has decreased by 21% YoY but it has increased by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.